How Do You Know It’s Psoriasis? Here Are The Signs And Symptoms You Should Look For
More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...
GlobalData on MSN7d
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 (IgG4) antibody, imsidolimab, to treat ...
The American Journal of Managed Care7d
GPP Flares Linked to Increased Hospitalizations, Health Care Costs, Study Finds
New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), ...
Le Lézard6d
Boehringer Canada Announces Availability of SPEVIGO® for expanded indication in Canada
Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue.1,2,3,4SPEVIGO's ...
Vanda Pharmaceuticals And Anaptys Announce Exclusive Global License Agreement For Vanda To Develop And Commercialize Imsidolimab, An IL-36R Antagonist
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis <li /> Vanda expects to immediately ...
Yahoo Finance7d
Boehringer Canada Announces Availability of SPEVIGO® for expanded indication in Canada
are now available in Canada for the treatment of generalized pustular psoriasis (GPP) in patients 12 years of age and older, weighing at least 40 kg. 5 The subcutaneous formulation for chronic GPP ...
Business Insider8d
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU Anaptys ...